{"preliminary_commentary":{"by_channel":{"x_thread":33,"youtube":3,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04379635\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-01T22:07:38.671Z","note":"Automated from the 37 newest of 39 indexed sources (Oct 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":37,"text":"- Whether adjuvant immunotherapy adds value, and which patients can forgo it\n- How biomarkers, including PD-L1, can guide treatment selection\n- How MRD or ctDNA could guide treatment decisions\n- How pathological response should be assessed and interpreted\n\nAlso discussed: cross-trial comparisons."},"drugs_tested":[["tislelizumab"]],"indication":"resectable stage II–IIIA non-small cell lung cancer","name":"RATIONALE-315","nct_id":"NCT04379635","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rationale-315-nct04379635. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Tislelizumab + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium","label":"Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Tislelizumab","type":"EXPERIMENTAL"},{"description":"Placebo + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium","label":"Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer"],"enrollment":{"count":453,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tislelizumab","otherNames":["BGB-A317"],"type":"DRUG"},{"name":"Cisplatin injection","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel injection","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed Disodium","otherNames":[],"type":"DRUG"},{"name":"Placebos","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-18","lead_sponsor":"BeiGene","official_title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy and Safety of Neoadjuvant Treatment With Tislelizumab (BGB-A317, Anti-PD-1 Antibody) or Placebo Plus Platinum-Based Doublet Chemotherapy Followed By Adjuvant Tislelizumab or Placebo in Resectable Stage II or IIIA Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Major pathological response (MPR) in Intent-to-Treat (ITT) analysis set","timeFrame":"Up to 3 months following completion of neoadjuvant treatment"},{"measure":"Event-free survival (EFS) in ITT analysis set as Assessed by the Blinded Independent Central Review (BICR)","timeFrame":"Up to 5 years"}],"references":[{"citation":"Wang C, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Zhang Z, Yao B, Wang S, Leaw S, Naicker K, Zheng W, Yu C, Yue D; RATIONALE-315 investigators. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial. Ann Oncol. 2026 Apr;37(4):544-554. doi: 10.1016/j.annonc.2025.11.017. Epub 2025 Dec 2.","pmid":"41344593","type":"DERIVED"},{"citation":"Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Cheng Y, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Yao B, Wang S, Wang RH, Zheng W, Wang C; RATIONALE-315 investigators. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025 Feb;13(2):119-129. doi: 10.1016/S2213-2600(24)00269-8. Epub 2024 Nov 21.","pmid":"39581197","type":"DERIVED"}],"start_date":{"date":"2020-05-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT04379635"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rationale-315-nct04379635"}